Immunogenicity of Adalimumab in Bacterial Molecular Mimicry: In Silico Analysis
{{output}}
Background: Adalimumab, a monoclonal antibody targeting tumor necrosis factor α, treats autoimmune diseases but induces antidrug antibodies in 30% to 60% of patients, reducing its efficacy. ... ...
